Related Experiment Video

Updated: Aug 14, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

Recent studies with eplerenone, a novel selective aldosterone receptor antagonist

E G McMahon1

  • 1Pharmacia Corporation, St Louis, Missouri 63167, USA. ellen.g.mcmahon@monsanto.com

Current Opinion in Pharmacology
|November 21, 2001
PubMed

Insights

Aldosterone activation worsens outcomes in heart failure and hypertension. New drug eplerenone shows promise in protecting the cardiovascular system, offering potential therapeutic benefits for these conditions.

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Pharmacology

Background:

  • Activation of the renin-angiotensin-aldosterone system (RAAS) is linked to poor outcomes in hypertension and congestive heart failure.
  • Elevated aldosterone levels remain a significant cardiovascular disease risk factor, even with existing treatments like ACE inhibitors and AT1 receptor antagonists.
  • Preclinical research suggests aldosterone exerts detrimental cardiovascular effects beyond its known renal actions.

Purpose of the Study:

  • To investigate the cardiovascular effects of aldosterone.
  • To evaluate the efficacy of the selective aldosterone receptor antagonist eplerenone in preclinical models.
  • To explore the potential therapeutic benefits of eplerenone in hypertension and heart failure.

Main Methods:

  • Review of preclinical data on aldosterone's cardiovascular effects.
  • Assessment of eplerenone's cardioprotective effects in experimental cardiovascular disease models.
  • Analysis of early clinical trial data for eplerenone in hypertension and heart failure patients.

Main Results:

  • Aldosterone activation strongly correlates with end-organ damage in cardiovascular disease.
  • Eplerenone demonstrated significant cardioprotective effects in experimental models.
  • Early clinical data indicate potential therapeutic benefits of eplerenone.

Conclusions:

  • Aldosterone has deleterious cardiovascular effects independent of its renal actions.
  • Eplerenone, a selective aldosterone receptor antagonist, offers significant cardioprotection.
  • Eplerenone may provide important therapeutic benefits for patients with hypertension and heart failure.

More Related Videos

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Related Concept Videos

Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...